Medication info
Janumax Tablet 25 Milligrams (Sitagliptin Phosphate Hydrate)

Janumax Tablet 25 Milligrams (Sitagliptin Phosphate Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate Hydrate›32.125mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Pink, double-convex, round, film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202400103 · Approved 2024.01.15 · Insurance code 644004770

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer this drug at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Blood sugar control in patients with type 2 diabetes
View approved original text

This medication assists in blood sugar control in patients with type 2 diabetes by augmenting dietary and exercise regimens. It can be used alone or in combination with other medications, contributing to the effective management of blood sugar and the prevention of complications.

How to take

Adult dose

Administer this drug at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions, so if symptoms such as skin rashes or difficulty breathing occur, it should be discontinued immediately and a doctor consulted. There is a risk of acute pancreatitis with this medication, so monitor for symptoms of pancreatitis such as abdominal pain or vomiting, and if suspected, stop the medication at once. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients with a history of hypersensitivity to this medication or its components. In patients with decreased renal function, dosage adjustment is required, and regular kidney function tests are important. During treatment with this drug, side effects such as upper respiratory infections, pharyngitis, headaches, diarrhea, nausea, etc., may occur; inform healthcare personnel if symptoms persist or worsen. When taken with insulin or sulfonylureas, there is an increased risk of hypoglycemia, so blood sugar levels should be checked frequently, and dosage adjustments may be necessary. If severe joint pain or skin blisters develop during treatment, discontinue use immediately and consult a doctor. Pregnant or breastfeeding women should avoid using this medication, and safety in pediatric patients under 18 years has not been established. In case of overdose, seek medical attention immediately for appropriate treatment; this medication can be partially removed by hemodialysis.

Side effects

Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative dermatitis, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory tract infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe and disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. Additionally, it is advisable to store the medication at room temperature between 1°C and 30°C. This storage method helps maintain the drug's efficacy.

Appearance and packaging

Appearance

Pink, double-convex, round, film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.